Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR
Latest press release
Latest press releases and news stories
Go to news archive
Featured News Article
19/12/2024
News story
Beyond trends: equipping the aesthetics community for what’s NEXT
14/12/2024
Press release
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
13/12/2024
Press release
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union
28/11/2024
Press release
Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis
Galderma Annual reviews